US 12,167,995 B2
[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester for treatment of chronic cough
Olivier Poirot, Lausanne (CH); and Ashley Woodcock, Lausanne (CH)
Assigned to Axalbion SA, Lausanne (CH)
Appl. No. 17/618,394
Filed by AXALBION SA, Lausanne (CH)
PCT Filed Jun. 10, 2020, PCT No. PCT/EP2020/066065
§ 371(c)(1), (2) Date Dec. 10, 2021,
PCT Pub. No. WO2020/249607, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 1908219 (GB), filed on Jun. 10, 2019.
Prior Publication US 2022/0265594 A1, Aug. 25, 2022
Int. Cl. A61K 31/223 (2006.01); A61P 11/14 (2006.01)
CPC A61K 31/223 (2013.01) [A61P 11/14 (2018.01)] 47 Claims
 
1. A method of treatment of refractory chronic cough (RCC) or idiopathic chronic cough (ICC) comprising administering to a patient in need thereof a therapeutically effective amount of a compound that is [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.